$350 Million

Horizon Therapeutics plc

Bookrunner, March 2015

Horizon Therapeutics plc
Exchangeable senior notes offering

Horizon Pharma is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. Horizon has two operating segments, the orphan and rheumatology segment and the primary care segment. Horizon’s strategy is to build a robust and differentiated pipeline and to maximize growth of its marketed rare disease medicines, in particular, KRYSTEXXA, its medicine for uncontrolled gout